Login / Register


Password: [Lost?]

New User? Click here for your FREE subscription

Physical Therapists & PT Assistants
Physical Therapists & PT Assistants Physical Therapists & PT Assistants

Follow Us

NEWS-Line on Twitter NEWS-Line on Facebook NEWS-Line on Google+ NEWS-Line on LinkedIn NEWS-Line on Pinterest

Physical Therapist Conferences &
Educational Opportunities

Feb. 23 - 23

Combined Sections Meeting


April 23 - 23

Mobility Conference


More Events

New Drug Expands Treatment Opportunities For Rheumatoid Arthritis | NEWS-Line for Physical Therapists & PT Assistants

New Drug Expands Treatment Opportunities For Rheumatoid Arthritis


In its final Phase III clinical trial, a new drug for treating rheumatoid arthritis has proved to be at least as effective as the current "gold standard" treatment for this autoimmune disease. This opens up new treatment options for affected patients. The results of the international multicentre study led by MedUni Vienna were recently published in the prestigious "New England Journal of Medicine".

Currently, a combination of the drugs adalimumab (which inhibits the mediator of inflammation TNF (tumour necrosis factor)) and methotrexate (a folic acid antagonist) is one of the most effective options ("gold standard") for patients who fail to respond adequately to initial treatment with methotrexate. Despite this and other effective drug regimens, up to 25% of patients do not respond well to any of the currently available therapeutic options. The new drug olokizumab is a humanised monoclonal antibody that directly targets the interleukin-6 cytokine. This is a messenger molecule that, like TNF, activates inflammatory responses in the body and is involved in the progression of joint damage in rheumatoid arthritis. Olokizumab is the first direct inhibitor (blocker) of interleukin-6 which will soon be filed for approval for commercial use for this indication.

In this Phase III clinical trial with more than 1,600 volunteers, the efficacy of the new drug in combination with methotrexate was tested against placebo and adalimumab plus methotrexate. This new therapy proved to be more efficacious than placebo and at least as effective as the current gold standard. "The new drug helps many patients with rheumatoid arthritis who failed methotrexate to achieve so-called low disease activity, which is the primary therapeutic goal in this population. Complete disappearance of symptoms of active disease, so called remission, occurs in 1 out of 8 patients," explains study lead Josef Smolen from the Division of Rheumatology within the Department of Medicine III at MedUni Vienna and University Hospital Vienna. "This new therapy will significantly expand the range of treatment options, since this agent has a different mode of action than all other drugs."

"This will give us another excellent treatment opportunity for our patients," explains Daniel Aletaha, Head of the Division of Rheumatology. "We soon will have another option for those patients who do not respond to a first or subsequent therapies."

The new drug is about to be filed for approval in the EU and the USA within the coming year. The researchers expect it to be in clinical use soon thereafter.

About rheumatoid arthritis
Rheumatoid arthritis is a chronic autoimmune disease that primarily affects women (approximately two thirds of those affected) and is usually diagnosed between the ages of 40 and 70. Approximately 1% of the world’s population suffers from rheumatoid arthritis. The disease causes inflammation of the joints, resulting in swelling, overheating and functional impairments. If left untreated, it leads to gradual destruction of the joints and the neighbouring bone, causing misalignment, malformation, and permanent and progressive disability. Around 80,000 people in Austria suffer from this disease.

Publication: New England Journal of Medicine
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis
Josef S. Smolen, Eugen Feist, Saeed Fatenejad, Sergey A. Grishin, Elena V. Korneva, Evgeniy L. Nasonov, Mikhail Y. Samsonov, and Roy M. Fleischmann, for the CREDO2 Group;
N Engl J Med 2022;387:715-26. DOI: 10.1056/NEJMoa2201302

Medical University of Vienna
Medical University Vienna (MedUni Vienna) is one of the most traditional medical education and research facilities in Europe. With almost 8,000 students, it is currently the largest medical training centre in the German-speaking countries. With 6,000 employees, 30 departments and two clinical institutes, 13 medical theory centres and numerous highly specialised laboratories, it is also one of Europe's leading research establishments in the biomedical sector.

Source: Medical University of Vienna

Share This!

Physical Therapist Jobs

Physical Therapist - $75k per year - $5,000 Sign-on Bonus - Recent Graduates Welcome! Diem positions available

Elizabeth Seton Children’s
Yonkers, New York

Physical Therapist - Sign on Bonus & Relocation offered

Carolinaeast Health System
New Bern, North Carolina

Physical Therapist - Private Office - Full or Part Time

Comprehensive Physical Therapy & Sports Medicine
Paterson (minutes from NYC) , New Jersey

Physical Therapists

Regional West Health Services
Scottsbluff, Nebraska

Physical Therapist (PT) - Full Time & Part Time

Integrated Musculoskeletal & Spine Group
Freeport, New York

Physical Therapist or New Grad

Kinetic Institute Physical Therapy
Sanford (35 minutes from Raleigh) , North Carolina

More Jobs
(Dismiss) Thank you for visiting NEWS-Line! Please sign up, login, or follow us on your favorite social networks
to receive custom tailored eNews, job listings, and educational opportunities for your specific profession.